In November 2025, PROMOMED-Animal Health participated in the National Veterinary Congress (NVC-2025)

During the three days of the congress, her stand was visited by more than 1,000 practitioners from different regions of Russia.

In a conversation with representatives of the press, Sergey Lvov, Executive Director of PROMOMED-Animal Health LLC, spoke in detail about the developments, production features and quality control. He stressed that all veterinary drugs are created and manufactured in accordance with high standards, and the main principle of the company's work is "the production of veterinary drugs of pharmaceutical quality."

The key event for the company was the presentation of new products: the broad-spectrum antibiotic Amklav® Vet, as well as selective nonsteroidal anti-inflammatory drugs for dogs Flexonorm® and for cats Flexonorm® Cat.

As part of the scientific program, the company organized a satellite report "Rational antibiotic therapy of canine pyoderma." In it, the head of the Department of Dermatology at the Biocontrol Veterinary Clinic, E.V. Kornyushenkova, highlighted the importance of choosing antibiotics for the treatment of skin diseases and drew the attention of doctors to the quality and convenience of using Amklav®. Vet in practice. The report attracted the attention of more than 150 specialists.

The line of anti-inflammatory drugs Flexonorm® and Flexonorm® Cat also aroused great interest among practitioners. These products provide long-term control of pain and inflammation in acute and chronic conditions, taking into account the specific characteristics of dogs and cats. The stand discussed the specifics of the use of drugs, safety issues during a long course, as well as the possibility of their use in complex therapy for surgical interventions, chronic diseases of the musculoskeletal system and other pathologies.

During negotiations with opinion leaders and heads of the country's leading clinics, agreements were reached on conducting joint clinical and post-marketing studies of the company's drugs.